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Abstract 
Triple negative breast cancer (TNBC) is an aggressive disease with a 5-y relative survival rate of 11% after distant metastasis. To 
survive the metastatic cascade, tumor cells remodel their signaling pathways by regulating energy production and upregulating 
survival pathways. AMP-activated protein kinase (AMPK) and Akt regulate energy homeostasis and survival, however, the individual 
or synergistic role of AMPK and Akt isoforms during lung colonization by TNBC cells is unknown. The purpose of this study 
was to establish whether targeting Akt, AMPK α or both Akt and AMPK α isoforms in circulating cancer cells can suppress TNBC 
lung colonization. Transient silencing of Akt1 or Akt2 dramatically decreased metastatic colonization of lungs by inducing apoptosis 
or inhibiting invasion, respectively. Importantly, transient pharmacologic inhibition of Akt activity with MK-2206 or AZD5363 
inhibitors did not prevent colonization of lung tissue by TNBC cells. Knockdown of AMPK α1, AMPK α2, or AMPK α1/2 also 
had no effect on metastatic colonization of lungs. Taken together, these findings demonstrate that transient decrease in AMPK 
isoforms expression alone or in combination with Akt1 in circulating tumor cells does not synergistically reduce TNBC metastatic lung 
colonization. Our results also provide evidence that Akt1 and Akt2 expression serve as a bottleneck that can challenge colonization of 
lungs by TNBC cells. 
Neoplasia (2021) 23, 429–438 
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Introduction 
Breast cancer is the second leading cause of cancer death among women 
globally, and projections estimate that there will be over 42,000 deaths in the 
United States in 2020 [1] . Most deaths are due to metastatic spread of the 
cancer to the lungs, brain or bone [2] . Triple negative breast cancer (TNBC) 
is an aggressive subtype of breast cancer that comprises 15% to 20% of overall 
cases [3-7] . TNBC, characterized by a lack of expression of the estrogen and 
progesterone receptors and no overexpression of the HER2 protein, consists 
Abbreviations: Akt, Protein kinase B; AMPK, AMP-activated protein kinase; ER+, 
Estrogen receptor-positive; FBS, Fetal bovine serum; GFP, Green fluorescent protein; 
IHC, Immunohistochemistry; NSG, NOD-scid IL2Rgamma null ; PBS, Phosphate buffered 
saline; PS, Pencillin-streptomycin; RPMI, Roswell Park Memorial Institute; siRNA, Small 
interfering RNA; TNBC, Triple negative breast cancer; WB, Western blot. 
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of a diverse group of tumors that affect younger women and are found 
with greater frequency in African Americans [6–9] . TNBC is resistant to 
targeted therapy and is more likely than other breast cancer types to recur 
and metastasize to distant organs [6–9] . Lungs are the primary site of TNBC 
colonization with approximately 40% of TNBC metastases occurring in the 
lungs [10] . The survival rate for TNBC significantly decreases once it has 
metastasized to systemic organs [11] . The 5-y relative survival rate of localized 
TNBC is 91%, and falls to 65% with regional metastasis; however, survival 
precipitously drops to 11% with distant spread [11] . TNBC patients with 
lung metastases have a median survival of only 15 mo [12] . Understanding 
the mechanism of TNBC metastatic spread to lungs and preventing the 
establishment of micrometastases in distant organs will directly improve 
patient survival. 
Metastasis is a multistep process that requires cells to follow five sequential 
steps: infiltrate surrounding tissue, intravasate into a blood or lymphatic 
vessel, survive during transit, extravasate into an organ, and proliferate to 
form colonies [13] . Cells must become motile before infiltrating surrounding 
tissue, and they undergo the epithelial-to-mesenchymal transition to increase 
migratory ability [13] . Once in a vessel, cells travel and must survive until 
they lodge in capillaries or adhere to endothelial cells of the vessel wall [14] . 
Cells then extravasate into surrounding tissue within a few hours [14] . After 
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arriving at a distant site, metastatic cells rely on oncogenes to promote survival 
[14] . Only a subset of surviving cells proliferates to form a colony [14] . 
Metastasis is extremely inefficient with less than 0.1% of cells surviving at 
distant sites [13] . Survival during transport and extravasation into an organ 
are key steps in early-stage metastasis that can be targeted to prevent the 
establishment of colonies at distant sites. Since metastasis to distant organs 
happens in a short timeframe, we decided to identify the role of key survival or 
metabolism proteins by regulating their expression in circulating cancer cells. 
This model focuses specifically on the fate of cancer cells after intravasation 
but before proliferation of micrometastases. 
During organ metastasis, cells rely on increased energy production and 
oncogene expression to adapt to stressful conditions [ 14 , 15 ]. Inhibiting 
pathways that help cells alter metabolism or overcome stresses during 
early-stage metastasis may reduce their ability to successfully metastasize. 
Akt and AMP-activated protein kinase (AMPK) are 2 proteins that play 
crucial roles in cellular survival and metabolism, respectively. Moreover, Akt 
and AMPK reciprocally regulate each other during matrix attachment and 
detachment in breast cancer [16] . Akt promotes growth of matrix-attached 
cells, while AMPK increases energy availability for matrix-detached cells [16] . 
Concurrently targeting signaling through Akt and AMPK may synergistically 
reduce the ability of TNBC to metastasize. 
Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), is 
composed of three isoforms: Akt1, Akt2, and Akt3 [17–22] . Akt promotes 
cellular growth and survival by phosphorylating and regulating many targets, 
including the mammalian target of rapamycin (mTOR) [17–22] . The 
ability of Akt1 and Akt2 to control metastasis of estrogen receptor-positive 
(ER + ) and HER2-amplified breast cancers has previously been studied. 
Akt1 inhibits metastasis of both breast cancer subtypes, while Akt2 has a 
prometastatic role in both cases [23–25] . However, the impact of Akt1 and 
Akt2 on TNBC metastasis is unknown. AMPK is a heterotrimeric complex 
composed of an α catalytic subunit and β and γ regulatory subunits [26–
30] . The catalytic domain is comprised of α1 and α2 isoforms [26–30] . 
AMPK is a major metabolic regulator that maintains energy homeostasis of 
cells by increasing ATP production and reducing ATP consumption [26–
30] . In particular, AMPK reduces lipid synthesis and stimulates fatty acid 
oxidation by phosphorylating acetyl CoA carboxylase [26–29] . Both fatty 
acid synthesis and oxidation can promote metastasis [31] . AMPK may play a 
key role in balancing flux through these pathways during different stages of 
metastasis. However, the specific steps of TNBC metastasis that are regulated 
by AMPK α1 and AMPK α2 are unclear. Moreover, combined targeting of 
individual Akt and AMPK α isoforms to reduce TNBC metastasis has not 
been previously examined. 
Here, we used transient knockdown to determine the roles of Akt and 
AMPK α isoforms during systemic dissemination and whether synergistic 
knockdown of both Akt and AMPK α can block TNBC metastasis-initiating 
cell colonization of lungs. We found that silencing either Akt1 or Akt2 
dramatically decreased lung colonization of TNBC cells by inducing 
apoptosis or inhibiting invasion, respectively. Knockdown of AMPK α1, 
AMPK α2, AMPK α1/2 or suppression of Akt activity with small molecule 
drugs did not prevent lung metastasis. Taken together, our findings 
demonstrate that reduction in Akt1 or Akt2 expression, but not activity, may 
directly decrease mortality from metastatic cancer in TNBC patients. 
Materials And methods 
Materials 
Roswell Park Memorial Institute (RPMI) 1640 medium was from 
Thermo Fisher (Waltham, MA). DMEM/F12 was from Sigma-Aldrich 
(St. Louis, MO). Fetal bovine serum (FBS), 100x penicillin-streptomycin 
solution (PS), and Dulbecco’s Phosphate Buffered Saline (PBS) were 
from Sigma-Aldrich. Opti-MEM and Lipofectamine RNAiMAX were 
from Thermo Fisher. Protein Assay Dye was from Bio-Rad (Hercules, 
CA). Amersham ECL Prime Western Blotting Detection Reagent was 
from GE Healthcare Life Sciences (Chicago, IL). Immobilon Western 
Chemiluminescent HRP Substrate was from Millipore (Burlington, MA). 
Pooled siRNAs for AMPK α1, AMPK α2, and AMPK α1/2 were from Santa 
Cruz Biotechnology (Dallas, TX). Pooled siRNAs for Akt1 and Akt2 were 
from Thermo Fisher. MISSION pLKO.1-puro-CMV-TurboGFP Positive 
Control Transduction Particles (Sigma-Millipore; #SHC003V) were used 
to establish MDA-MB-231 green fluorescent protein (GFP) cells. MK- 
2206 2HCl and AZD5363 were from Cayman Chemical (Ann Arbor, 
MI). Primary antibodies used in this study include: Abcam: (1) AMPK α1, 
ab32047 (1:1000 for WB and 1:250 for IHC) and (2) AMPK α2, ab3760 
(1:1000 for WB and 1:500 for IHC); Cell Signaling Technology (Danvers, 
MA): (1) pAkt, #4060 (1:2000 for WB), (2) Akt1, #75692 (1:1000 for WB), 
(3) Akt2, #3063 (1:1000 for WB), (4) Cleaved PARP, #5625 (1:1000 for 
WB), (5) ZO-1, #8193 (1:1000 for WB), (6) ZEB1, #3396 (1:1000 for WB), 
(7) Claudin-1, #13255 (1:1000 for WB), (8) E-cadherin, #3195 (1:1000 for 
WB), (9) Vimentin, #5741 (1:1000 for WB), (10) β-catenin, #8480 (1:1000 
for WB), (11) Snail, #3879 (1:1000 for WB), (12) Bcl-2, #4223 (1:1000 
for WB), (13) Bcl-xL, #2764 (1:1000 for WB), (14) Mcl-1, #5453 (1:1000 
for WB), (15) Bim, #2933 (1:1000 for WB), (16) Bad, #9239 (1:1000 for 
WB), and (17) BID, #2202 (1:1000 for WB); and Sigma-Aldrich: β-actin 
(1:10,000 for WB). Akt1, #sc-5298 (1:500 for IHC), Akt2, #sc-5270 (1:500 
for IHC), and secondary antibodies were from Santa Cruz Biotechnology. 
Cell culture 
TNBC cells (MDA-MB-231 and MDA-MB-468 cells) were from the 
American Type Culture Collection and cultured in a humidified incubator 
at 37 °C and 5% CO 2 . MDA-MB-231 cells were cultured in RPMI + 10% 
FBS + 1% PS. MDA-MB-468 cells were cultured in DMEM/F12 + 10% 
FBS + 1% PS. To generate MDA-MB-231 GFP cell line, 5000 cells were 
seeded into a 96-well plate and incubated at standard cell culture conditions 
overnight. On the following day, cells were transfected with GFP lentiviral 
particles (MOI = 40) in medium supplemented with 10 μg/mL polybrene. 
The medium was changed after 24 h, and cells were seeded 24 h later 
into a 24-well plate. The cells were selected the next day with 1 μg/mL of 
puromycin. 
siRNA transfection 
TNBC cells were transfected with 50 nM of siRNA to NTC, Akt1, 
Akt2, AMPK α1, AMPK α2, or AMPK α1/2. The siRNAs were mixed with 
Lipofectamine RNAiMAX in Opti-MEM for 20 min. The ratio of Opti- 
MEM to complete medium was 1:4. Medium was changed every 24 h until 
cells were injected into mice or lysed for western blotting. 
Western blotting 
TNBC cells were seeded and then transfected as described above. Medium 
was changed after 24 h and again after 48 h. After incubation for a total of 
72h, medium was removed, and cells were washed with ice cold 1 × PBS. 
Cells were then scraped and lysed in 1 × radioimmunoprecipitation assay 
buffer containing 1 mM phenylmethylsulfonyl fluoride. Cells were incubated 
on ice for 20 min with 10-s vortexes every 5 min before centrifugation at 
14,000 rpm for 20 min at 4 °C. Protein concentrations in the lysates were 
then determined. Equal amounts of protein were reduced and denatured 
by heating at 80 °C for 10 min before being resolved on 4% to 12% Bis- 
Tris gels. The proteins were then transferred to polyvinylidene fluoride) 
membranes, blocked with 10% milk for at least 1 h, and incubated in primary 
antibody solutions overnight at 4 °C. On the next day, the membranes 
were washed twice with 1 × Tris-buffered saline with Tween 20 (TBST) 
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for 5 min and 10 min before incubation with secondary antibody solutions 
(1:10,000 dilutions) for 1h at room temperature. The membranes were then 
washed twice with TBST for 15 min and 20 min before Amersham ECL 
or Immobilon was added to the membranes for protein detection. Stripping 
buffer was used on membranes where required. 
Immunohistochemistry 
Samples of TNBC lymph node or lung metastases were identified by 
the Markey Cancer Center Biospecimen Procurement and Translational 
Pathology shared resource facility. Immunohistochemistry (IHC) was 
performed as previously described [32] . Briefly, slides were deparaffinized in 
xylene, rehydrated, incubated for 15 min with fresh 0.3% hydrogen peroxide, 
washed with PBS, and heated to 95 °C in 10 mM citrate buffer (pH 6.0; 30 
min) for Akt1 and Akt2 antibody staining. Antigen retrieval for slides stained 
with AMPK α1 and AMPK α2 antibody was performed in Diva Decloaker, 
RTU (Biocare Medical; # DV2004G1) buffer. Antigen retrieval for sliders 
stained with Akt1 and Akt2 were performed in sodium citrate buffer (10 mM 
Sodium Citrate, 0.05% Tween 20, pH 6.0). 
Endogenous peroxidase activity was blocked with Bloxall blocking 
solution (Vector Laboratories; # SP-6000). Next, sections were blocked for 1 
h with 2.5% normal horse serum (Vector Laboratories; #S-2012). AMPK α1, 
AMPK α2, Akt1, and Akt2 antibodies were diluted in Dako background 
reducing antibody diluent (Agilent Dako; #s3022). Primary antibody was 
incubated with slides for 12 h at 4 °C in a humidifier chamber, washed with 
TBST (Tris-Buffered Saline and Tween 20) and incubated with ImmPRESS 
universal antibody IgG polymer detection kit (Vector Laboratories, #MP- 
7500) for 1 h, RT. Antibody reaction was visualized with Immpact DAB 
EqV peroxidase substrate (Vector Laboratories, #SK-4103). All sections were 
counterstained with hematoxylin (VWR; #95057-844) and observed by light 
microscopy. For negative controls, primary antibody was omitted from the 
above protocol. 
The number of positive cells was visually evaluated in each core by 
a pathologist (EL) and the staining intensity was classified using a semi- 
quantitative seven-tier system developed by Allred et al. [ 33 , 34 ]. The system 
assesses the percentage of positive cells (none = 0; < 10% = 1; 10% to 50%, 
= 2; > 50% = 3) and intensity of staining (none = 0; weak = 1; intermediate = 2; 
and strong = 3). 
TNBC lung metastasis model 
NOD-scid IL2Rgamma null mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME). Housing for these animals was maintained 
in a HEPA-filtrated environment within sterilized cages with 12 h light/12 
h dark cycles. All animal procedures were conducted with approval of and in 
compliance with the University of Kentucky Institutional Animal Care and 
Use Committee. 
Knockdown of Akt and AMPK isoforms in circulating cancer cells was 
achieved by transient knockdown of protein expression in vitro, as described 
above, and injection of cancer cells intravenously (iv) into mice 48 h after 
transfection. Briefly, cells were washed with 1 × PBS 48 h after transfection, 
trypsinized, counted and resuspended in PBS at a density of 1 × 10 6 cells 
per 100 μL. Cells were kept on ice before intravenous injection. For iv 
injection of MDA-MB-231 GFP cells, NOD-scid IL2Rgamma null mice were 
anesthetized with isoflurane (induction 4%, maintenance 2%). The viability 
of cells used for inoculation was greater than 95% as determined by Vi- 
CELL TM XR (Beckman Coulter); 1 × 10 6 cells were injected per animal. 
Gentle pressure was applied to the inoculation site until there was no visible 
sign of bleeding. GFP fluorescence imaging was performed using an LT- 
9500 Illumatool/TLS (Lightools Research, Encinitas, CA), equipped with 
an excitation source (470 nm) and filter plate (515 nm). Lung metastasis in 
AZD5363 treatment experiment was also imaged with Lago imaging system 
(Spectral Instruments, Tucson, AZ) and analyzed in Aura software (Spectral 
Instruments, Tucson, AZ). 
Pharmacologic inhibition of Akt activity with MK-2206 or AZD5363 
compounds 
GFP-expressing MDA-MB-231 cells were treated with MK-2206 or 
AZD5363 (0 or 10 μM). After 22 h, medium was replaced with fresh 
medium containing MK-2206 or AZD5363 (0 or 10 μM) for an additional 
2 h. Treatment with chemical inhibitors for 24 h + 2 h was performed to 
achieve continuous and prolonged Akt inhibition in TNBC cells prior to iv 
cells injection [35–37] . Cells were then collected, counted, washed in PBS, 
resuspended in PBS and injected into tail vein of mice (1 × 10 6 cells; 100 
μL). 
Analysis of GFP signal in TNBC lung metastases 
ImageJ software was used to evaluate GFP signal in TNBC lung 
metastases. ImageJ is a Java-based image processing program developed 
at the National Institutes of Health and the Laboratory for Optical and 
Computational Instrumentation (LOCI, University of Wisconsin; https:// 
imagej.nih.gov/ ). Photographs of lung metastases were opened in ImageJ 
software and split into channels (Image-Color-Split Channels). Blue and red 
channels were closed, and the green channel was adjusted with threshold 
function (Image-Adjust-Threshold; select B&W in drop-down menu). Next, 
a rectangular selection area was drawn over a lung to perform measurement of 
mean gray values. Analysis properties were set to “area” and “Mean grey value”
(Analyze-Set Measurement). Mean grey values in the rectangular selection 
area drawn over a lung were analyzed and recorded (Analyze-Measure). To 
keep the area of selection consistent, the rectangular selection area was moved 
over the next lung and the analysis was repeated (Analyze-Measure). 
Statistical analysis 
Descriptive statistics, including means and standard deviations (SD), are 
presented for each experimental group and displayed in bar graphs while 
frequencies and proportions of IHC score were summarized for Akt and 
AMPK. Comparisons of green fluorescence area were performed using the 
one-way analysis of variance (ANOVA) with Holm’s adjustment for multiple 
testing between groups. The χ 2 test for goodness of fit was used to test 
departures from equality of proportions across IHC scores. P < 0.05 was 
considered to indicate a statistically significant difference. Statistical analyses 
were performed using SAS software version 9.4 (SAS Inc., Cary, NC, USA). 
Results 
Expression of Akt and AMPK α isoforms in TNBC lymph node or lung 
metastases 
Akt and AMPK α promote cellular survival and energy mobilization and 
may facilitate organ colonization during metastatic spread [ 16 , 18 , 38–
42 ]. We have previously shown that AMPK α1 and AMPK α2 are expressed 
in primary TNBC patient samples [43] . Here, we examined expression 
and subcellular localization of Akt and AMPK α isoforms in TNBC lymph 
node metastasis ( n = 45 patient samples). Fig 1 A indicates the cytoplasmic 
scoring distribution for each isoform; Akt1, Akt2, and AMPK α1 received 
scores of 5 or 6 in over 70% of cases, indicating intense and widespread 
cytoplasmic expression among the lymph node metastases. Chi-square tests 
indicated statistically significant higher IHC scores for Akt1, Akt2, and 
AMPK α1. AMPK α2 had slightly lower scores than the other proteins, with 
over 80% of samples being scored as a 4 or 5; cytoplasmic expression of 
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Fig. 1. Analysis of Akt1, Akt2, AMPK α1, and AMPK α2 expression in TNBC lymph node and lung metastases. (A) IHC scoring of Akt1, Akt2, AMPK α1, and 
AMPK α2 cytoplasmic expression in TNBC lymph node metastases. Samples were scored on scales of 0-3 for both intensity and distribution percentage, and the 
values were added together ( n = 45). (B) Subcellular localization of Akt1, Akt2, AMPK α1, and AMPK α2 in TNBC lymph node metastases ( n = 45). (C) IHC 
scoring of Akt1 and Akt2 cytoplasmic expression in TNBC lung metastases. Samples were scored on scales of 0-3 for both intensity and distribution percentage, 
and the values were added together ( n = 6). (D) Subcellular localization of Akt1 and Akt2 in TNBC lung metastases ( n = 6). IHC, Immunohistochemistry; 
TNBC, triple negative breast cancer. 
AMPK α2 is moderately strong and widespread among the patient samples. 
Supplementary Figs S1-S4 contain representative photographs of Akt1, 
Akt2, AMPK α1 or AMPK α2 from all patient samples. 
Fig 1 B compares the subcellular localization of Akt1, Akt2, AMPK α1, 
and AMPK α2 within the TNBC lymph node metastases. Akt1, Akt2, and 
AMPK α1 were predominantly expressed in the cytoplasm; nuclear and 
cytoplasmic localization was observed in a minority of cases; nuclear only 
localization was not observed in any cases. AMPK α2 had a substantially 
different subcellular localization pattern than Akt1, Akt2, or AMPK α1. 
AMPK α2 was expressed in both the nucleus and the cytoplasm. This data 
demonstrates predominant nuclear localization of AMPK α2 compared to 
predominant cytoplasmic expression of Akt1, Akt2, and AMPK α1 isoforms. 
Taken together, these results demonstrate strong and widespread expression 
of Akt and AMPK isoforms in TNBC lymph node metastases. 
We extended our analysis to include expression and subcellular 
localization of Akt1 and Akt2 isoforms in TNBC lung metastasis ( n = 6 
patient samples). Fig 1 C denotes the cytoplasmic scoring distribution for 
both isoforms; Akt1 and Akt2 received scores of 5 or 6 in all samples, 
indicating intense and widespread cytoplasmic staining among the TNBC 
lung metastases. Supplementary Figs S5 and S6 contain representative 
photographs of Akt1 or Akt2 from all patient samples. Fig 1 D compares the 
subcellular localization of Akt1 and Akt2 within the TNBC lung metastases. 
Akt1 was expressed in only the cytoplasm in all samples, while Akt2 was 
expressed in both the nucleus and the cytoplasm in 5 of the 6 samples. Taken 
together, these results indicate robust and extensive expression of Akt1 and 
Akt2 in TNBC lung metastases. 
AMPK isoforms expression is not crucial for lung colonization by 
MDA-MB-231 cells 
AMPK α is a key regulator of important metabolic pathways that 
promote metastasis [31] , but the role of individual AMPK α isoforms and 
metabolic pathways in circulating cancer cells survival and lung colonization 
is unknown. The metastatic cascade includes multiple steps – cell invasion, 
entry into vasculature, systemic circulation, arrest, and extravasation in 
secondary organs [44] . Therefore, we used transient knockdown approach 
to examine role of AMPK α1 or AMPK α2 isoforms in select steps of 
the metastatic cascade – systemic circulation and lung colonization. The 
expression of AMPK α1 or AMPK α2 proteins restored to original levels 48 h 
after intravenous injection of cancer cells [ 45 , 46 ]. Fig 2 A indicates AMPK α1 
and AMPK α2 silencing 72 h after siRNA transfection in MDA-MB-231 and 
MDA-MB-468 cells. MDA-MB-231 GFP cells with transient knockdown 
of AMPK α1/2 expression were prepared 48 h after transfection with siRNA 
for injection into mice. As shown in Fig 2 B, silencing AMPK α1/2 did not 
alter the ability of MDA-MB-231 cells to establish lung metastases. Taken 
together, these findings suggest that energy balance regulation by AMPK 
during cancer cells systemic circulation is not essential for lung colonization 
by TNBC cells. 
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Fig. 2. AMPK α isoforms expression in TNBC lung colonization. (A) MDA-MB-231 and MDA-MB-468 cells were transfected with 50 nM of siRNA 
targeting AMPK α1 or AMPK α2. Expression of AMPK α1, AMPK α2, β-catenin, Snail, ZO-1, E-cadherin, and Zeb1 was analyzed by western blot 72 h 
after transfection. (B) MDA-MB-231 GFP cells were transfected 50 nM siRNA targeting AMPK α1/2 and 100 nM for NTC. Cells were collected 48 h after 
transfection and injected intravenously into NSG mice. MDA-MB-231 lung metastasis was visualized with fluorescence imaging 36 d later. (C) MDA-MB- 
231 cells were transfected with siRNA targeting Akt1, AMPK α1, or Akt1/AMPK α1. Expression of Akt1, AMPK α1, cleaved PARP, and Bim was detected 72 
h after transfection. (D) MDA-MB-231 GFP cells were transfected with siRNA targeting Akt1, AMPK α1, or Akt1/AMPK α1. Transfection concentrations 
were: (1) individual siRNA: 50 nM, (2) combination siRNA: 50 nM each (100 nM total), and (3) NTC: 100 nM. Cells were collected 48 h after transfection 
and injected intravenously into NSG mice. MDA-MB-231 lung metastasis was visualized with fluorescence imaging 40 d later. NTC, Non-targeting control 
was used as a negative control. 
Breast cancer cell survival in suspension is dependent on 
pAMPK high /pAkt low status [16] . Therefore, we next determined whether 
TNBC cells also depend on AMPK and Akt expression or activity. Analysis 
of cancer cells survival after silencing AMPK α1 and Akt1 alone or in 
combination is demonstrated in Fig 2 C. Depleting Akt1 levels induced 
PARP cleavage and increased Bim expression, but combined knockdown 
with AMPK α1 did not enhance PARP cleavage or Bim expression ( Fig 2 C). 
We then transiently knockdown of AMPK α1 and Akt1 expression alone 
or in combination in MDA-MB-231 GFP cells before injecting into 
mice. As shown in Fig 2 D, silencing AMPK α1 did not alter the ability 
of MDA-MB-231 cells to establish lung metastases. However, suppressing 
Akt1 expression dramatically decreased MDA-MB-231 lung metastasis. 
Combined knockdown of AMPK α1 and Akt1 also did not synergistically 
suppress TNBC cells lung colonization. Taken together, these findings 
indicate that AMPK α isoforms play limited role in TNBC cells lung 
colonization, however, Akt1 appears to play a key role in facilitating TNBC 
lung colonization. 
Next, we examined what role Akt activation plays in the dramatic 
decrease in MDA-MB-231 lung metastasis observed after Akt1 knockdown. 
First, we suppressed Akt activity in MDA-MB-231 cells with MK-2206, 
an allosteric Akt inhibitor, prior to iv cell injection. MK-2206 treatment 
reduced Akt activity in MDA-MB-231 cells ( Fig 3 A) but had no effect 
on lung colonization ( Fig 3 B). We repeated the study with AZD5363, a 
small molecule inhibitor that causes Akt to enter a hyperphosphorylated, 
but catalytically inactive state [37] . Administration of AZD5363 induced 
Akt hyperphosphorylation ( Fig 3 C) but did not reduce TNBC lung 
colonization ( Fig 3 D). We next examined whether MK-2206 or AZD5363 
affect expression of Akt1 or Akt2 isoforms in TNBC cells. In Fig 3 E, we 
compared the relative abilities of siAkt, MK-2206, and AZD5363 to alter 
Akt1 expression. siAkt1 administration robustly reduced Akt1 expression 
while inducing PARP cleavage and increasing Bim expression. In contrast, 
treatment with MK-2206 or AZD5363 induced very minimal decreases 
in Akt1 expression. PARP cleavage was not detected with MK-2206 or 
AZD5363 treatment, indicating that these compounds are much weaker 
apoptotic agents than siAkt1. Moreover, neither MK-2206 nor AZD5363 
induced a substantial change in Akt2 expression ( Fig 3 F). Taken together, 
these findings indicate that TNBC lung colonization can be regulated 
through Akt1 expression in a manner independent of its phosphorylation 
status. 
Akt1 and Akt2 isoforms regulate MDA-MB-231 lung colonization 
Survival during systemic circulation and extravasation are essential steps 
for cells to establish distant metastases [ 13 , 14 ]. Therefore, proteins that 
prevent apoptosis or facilitate invasion may play a major role in promoting 
TNBC lung colonization. We first determined the differential expression of 
proteins essential for invasive properties of TNBC cells after knockdown 
of Akt isoforms. Knockdown of Akt2 decreased expression of Snail and 
Claudin-1 in MDA-MB-231 and MDA-MB-468 cells. However, silencing 
Akt1 had minor effect on Snail and Claudin-1 expression in MDA-MB-231 
and MDA-MB-468 cells ( Fig 4 A). Taken together, these findings indicate that 
Akt2 regulates expression of proteins that may promote lung colonization of 
circulating TNBC cells. 
We next determined role of Akt isoforms in TNBC apoptosis control. 
Akt1 knockdown induced PARP cleavage in both MDA-MB-231 and 
MDA-MB-468 cells, while silencing Akt2 led to robust PARP cleavage in 
MDA-MB-468 cells ( Fig 4 B). These findings suggest that either Akt1 or 
Akt2 knockdown promotes apoptosis induction in TNBC cells. Finally, we 
determined how silencing Akt1 or Akt2 impacted expression of Bcl2 family 
proteins, which regulate apoptosis induction. Akt1 knockdown increased 
the expression of Bim, a promoter of apoptosis, in MDA-MB-231 and 
MDA-MB-468 cells ( Fig 4 C). Silencing Akt2 reduced levels of Mcl-1, 
an antiapoptotic protein, in both MDA-MB-231 and MDA-MB-468 cells 
( Fig 4 C). Taken together, these findings indicate that Akt1 and Akt2 prevent 
apoptosis in TNBC cells by reducing Bim expression or upregulating Mcl-1 
levels, respectively. 
To conclude, we used siRNA directed toward Akt1 or Akt2 to evaluate the 
ability of each isoform to regulate TNBC lung metastasis. As shown in Fig 5 A, 
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Fig. 3. TNBC lung colonization is not dependent on Akt activation. (A) MDA-MB-231 GFP cells were treated with 10 μM MK-2206 for 22 h. Fresh 
medium with 10 μM MK-2206 was replaced 2 h before cells were collected and intravenously injected into NSG mice. Expression of pAkt (Ser473) was 
analyzed by western blot. (B) MDA-MB-231 lung metastasis was visualized with fluorescence imaging 46 d after cell injection. (C) MDA-MB-231 GFP cells 
were treated with 10 μM AZD5363 for 22 h. Fresh medium with 10 μM AZD5363 was replaced 2 h before cells were collected and intravenously injected 
into NSG mice. Expression of pAkt (Ser473) was analyzed by western blot. (D) MDA-MB-231 lung metastasis was visualized with fluorescence im aging 45 
d after cell injection. (E) Analysis of Akt1, cleaved PARP, and Bim expression in MDA-MB-231 cells treated with siAkt1 or MDA-MB-231 GFP cells treated 
with 10 μM MK-2206 or AZD5363 from (A) and (C), respectively, by western blot. (F) Analysis of Akt2 expression in MDA-MB-231 GFP cells treated with 
10 μM MK-2206 or AZD5363 from (A) and (C), respectively, by western blot. 
knockdown of either Akt1 or Akt2 dramatically decreased lung colonization 
of MDA-MB-231 cells. Silencing Akt1 or Akt2 blocked metastasis to a 
similar degree. Quantification of green fluorescence intensity with ImageJ 
indicated that both reductions were statistically significant ( Fig 5 A). Taken 
together, these findings suggest that reducing metastatic potential of TNBC 
by suppressing Akt1 and/or Akt2 expression is a potentially promising 
therapeutic strategy that may directly improve patient survival. 
Discussion 
Preventing metastatic spread of TNBC is crucial to improving patient 
survival. Akt and AMPK are two key proteins that serve vital functions for 
cancer cells during stress. The Akt signaling cascade promotes cellular survival 
by inhibiting apoptosis and facilitates cellular growth by stimulating cell cycle 
progression. AMPK is an important regulator of metabolism and helps cells 
maintain energy homeostasis in times of stress. Moreover, Akt and AMPK 
reciprocally regulate each other during matrix attachment and detachment in 
breast cancer [16] . The existence of this reciprocal regulatory loop prompted 
our interest in targeting both pathways together to block metastasis. We 
hypothesized that combined inhibition of Akt and AMPK would prevent 
TNBC lung colonization more than targeting either pathway alone, thereby 
improving patient survival. 
Mutations that activate the PI3K/Akt/mTOR pathway are frequently 
found in breast cancer [47] . However, the ability of individual Akt isoforms 
to mediate metastasis of TNBC cells is not well understood. We found 
that silencing Akt1 dramatically decreased lung colonization of circulating 
TNBC cells and induced PARP cleavage and Bim expression. Prior work has 
found that Akt1 maintains the viability of tumor-initiating cells by reducing 
Bim expression [39] . Therefore, our results indicate that Akt1 may support 
lung metastasis of circulating TNBC cells by preventing apoptosis induction. 
To our knowledge, this is the first study to establish that Akt1 expression 
promotes the in vivo metastatic potential of TNBC cells. Previous work has 
found that Akt1 blocks metastasis of other breast cancer subtypes [23–25] . 
Akt1 inhibits invasion of ER + breast cancer cells, and Akt1 overexpression 
attenuates HER2-mediated metastasis of murine mammary tumors [23–25] . 
TNBC is a very aggressive disease that is 4 × more likely to metastasize 
to viscera than non-TNBCs within the first 5 y [48] . Therefore, TNBC 
metastasis may be promoted by proteins that do not facilitate spread of other 
cancers. Our findings suggest that Akt1 is a key regulator of lung colonization 
in TNBC cells. 
Akt2 is more frequently amplified in cancer cells than Akt1, but its ability 
to regulate TNBC lung colonization is also unknown [18] . We found that 
silencing Akt2 significantly reduced TNBC lung colonization and suppressed 
expression of Snail, Claudin-1, and the anti-apoptotic protein Mcl-1. 
Claudin-1 promotes the invasive potential of nasopharyngeal carcinoma cells, 
and Snail is required for TNBC cells to invade into lymph nodes [ 49 , 50 ]. 
Therefore, our findings suggest that Akt2 may promote lung metastasis of 
circulating TNBC cells 2 ways: (1) facilitating extravasation through the 
vessel wall and into lung parenchyma and (2) preventing apoptosis induction. 
To our knowledge, this is the first study to identify Akt2 as a key mediator 
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Fig. 4. Akt isoforms promote invasion and suppress apoptosis in TNBC cells. (A) MDA-MB-231 and MDA-MB-468 cells were transfected with 50 nM of 
siRNA targeting Akt1 or Akt2. Expression of Akt1, Akt2, ZO-1, Claudin-1, E-cadherin, Vimentin, β-catenin, and Snail was analyzed by western blot 72 
h after transfection. (B) MDA-MB-231 and MDA-MB-468 cells were transfected with 50 nM siRNA targeting Akt1 or Akt2. Expression of Akt1, Akt2, 
and cleaved PARP was detected with western blot 72 h after transfection. (C) MDA-MB-231 and MDA-MB-468 cells were transfected with 50 nM siRNA 
targeting Akt1 or Akt2. Expression of Akt1, Akt2, and Bcl-2 family proteins was detected with western blot 72 h after transfection. NTC, Nontargeting control 
was used as a negative control. 
Fig. 5. Akt1 and Akt2 expression promote lung colonization of TNBC cells. (A) MDA-MB-231 GFP cells were transfected with 50 nM of siRNA targeting 
Akt1 or Akt2. Cells were collected 48 h after transfection and injected intravenously into NSG mice. MDA-MB-231 lung metastasis was visualized with 
fluorescence imaging 28 d later. (B) Summary diagram for the role of AMPK and Akt isoform expression in TNBC lung colonization. 
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of lung colonization in circulating TNBC cells. Prior work has indicated 
that Akt2 facilitates metastasis of other breast cancer subtypes [ 23 , 25 ]. Akt2 
promotes the migration and invasion of ER + breast cancer cells, and Akt2 
overexpression increases HER2-mediated metastasis of murine mammary 
tumors [ 23 , 25 ]. Our findings suggest that Akt2 is also an important regulator 
of metastasis in TNBC cells. 
Akt1 and Akt2 facilitate TNBC lung colonization independent of Akt 
activity. We showed that silencing Akt1 or Akt2 does not correlate with 
a substantial reduction in pAkt expression. This is most likely due to 
compensator y phosphor ylation of the isoform that is still present within 
the cells. Despite a corresponding reduction in pAkt levels, knockdown of 
Akt1 or Akt2 significantly suppressed TNBC metastasis. Other studies have 
also found a non-kinase function for Akt [ 51 , 52 ]. Akt1 has been shown 
to reduce toll-like receptor signaling in a kinase-independent fashion [51] . 
Moreover, Akt promotes cell survival in a kinase-independent manner and 
instead relies on its pleckstrin homology domain [52] . Akt1 and Akt2 may 
facilitate survival of circulating TNBC cells in a similar manner, but further 
work is needed to establish the underlying mechanisms. A prior study has 
found that overexpression of pAkt is correlated with an increased rate of brain 
metastasis in lung cancer patients [53] . Our findings suggest that the role of 
pAkt may vary between cancer types or that pAkt mainly stimulates growth 
of cells that have already colonized distant organs. 
Suppressing Akt1 and/or Akt2 expression is a novel therapeutic strategy 
that could be implemented for TNBC patients who are resistant to current 
therapeutic regimens. Our findings indicate that pharmacological reduction 
of Akt1 and/or Akt2 expression in TNBC patients with refractory tumors 
may prevent metastatic spread, thereby directly improving survival. Current 
clinical trials are focused on developing Akt inhibitors as therapeutic agents 
for breast cancer patients. However, we suggest that future studies should 
identify agents that can decrease Akt1 and/or Akt2 expression and evaluate 
their ability to limit metastasis of nonresponsive TNBC. 
In addition to Akt1 and Akt2, we also studied how AMPK α isoforms 
impact lung colonization. AMPK α is a major metabolic regulator that 
may balance energy demand during different stages of metastasis. When 
cells detach from a matrix, they are unable to import glucose and instead 
must increase ATP synthesis through other pathways [54] . AMPK α’s ability 
to mobilize energy via different metabolic pathways suggests that it may 
have an important role in restoring energy homeostasis for circulating cells. 
Moreover, fatty acid synthesis and oxidation—both of which are regulated 
by AMPK α—have been reported to promote metastasis [31] . Prior studies 
have found that AMPK α affects TNBC metastasis in an isoform-dependent 
fashion. AMPK α1 prevents metastatic spread of TNBC cells, while AMPK α2 
promotes metastasis of TNBC cells [ 55 , 56 ]. However, the specific stages of 
metastasis that are controlled by AMPK α1 and AMPK α2 in TNBC cells is 
unclear. In addition, combined inhibition of Akt and AMPK α isoforms has 
not been studied. We found that transiently silencing AMPK α1, AMPK α2, 
or AMPK α1/2 alone did not affect lung colonization of circulating MDA- 
MB-231 cells. Moreover, AMPK α knockdown did not synergistically block 
TNBC lung metastasis when combined with Akt isoform knockdown. These 
findings suggest that AMPK α1, AMPK α2, and AMPK α1/2 do not impact 
lung colonization of circulating MDA-MB-231 cells. 
Our findings expand on these prior studies, which used stable knockdown 
or overexpression cells instead of transiently transfected cells [ 55 , 56 ]. 
Unlike our experimental design, stable cell lines will not lose knockdown or 
overexpression after extravasation into tissue. As a result, previous work has 
not delineated whether AMPK α isoforms regulate metastasis of circulating 
TNBC cells or regulate proliferation of established microcolonies. Our 
findings indicate that neither AMPK α1 nor AMPK α2 impact survival or 
extravasation of circulating TNBC cells. However, AMPK α has been shown 
to affect TNBC cell growth [41–43] . We have previously reported that 
AMPK α1 and AMPK α2 promote cell cycle progression and proliferation 
in TNBC cells [43] . Moreover, pharmacological activators of AMPK α have 
also reduced growth and cell cycle progression of TNBC cells [57–59] . 
Therefore, the major effect of AMPK α isoforms on TNBC metastasis may 
involve growth regulation of cells that have already survived during systemic 
circulation and lung colonization. 
In summary ( Fig 5 B), we have shown that reducing Akt1 or Akt2 
expression prevents lung colonization of TNBC cells. Akt1 facilitates lung 
metastasis by inhibiting apoptosis induction, while Akt2 promotes lung 
metastasis by enabling extravasation through the vessel wall and into 
surrounding tissue. Silencing AMPK α1, AMPK α2, or AMPK α1/2 does 
not reduce lung colonization or synergistically block lung metastasis when 
combined with Akt isoform knockdown. Importantly, suppressing Akt1 
and/or Akt2 expression is a potentially promising therapeutic strategy that 
could reduce lung colonization and thus decrease mortality among TNBC 
patients. 
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